EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.812
https://www.valueinhealthjournal.com/article/S1098-3015(22)03016-9/fulltext
Title :
EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03016-9&doi=10.1016/j.jval.2022.09.812
First page :
Section Title :
Open access? :
No
Section Order :
10353